- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02832362
Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants
June 28, 2017 updated by: GlaxoSmithKline
A Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Local Nasal Tolerability and Safety of 1146A in Healthy Adult Subjects
This will be a single-center, randomized, parallel-group, placebo-controlled study to assess the local nasal tolerability and safety of multiple administrations of topically (intranasally) administered 1146A delivered by a nasal spray applicator in healthy adult participants
Study Overview
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Quebec City, Quebec, Canada, G1P 0A2
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form. Willing to be confined for 9 days (8 nights) and acceptance of standardized food and beverages throughout the confined study period
- Aged between 18 and 55 years inclusive
- Male or female
- Good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant and relevant abnormalities in medical history or upon physical and nasal examinations
- Participant is free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
- Females of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception. Adequate contraception is defined as abstinence, oral contraceptive, either combined or progestogen alone or injectable progestogen or implants of levonorgestrel or estrogenic vaginal ring or percutaneous contraceptive patches or intrauterine device or intrauterine system or double barrier method (condom or occlusive cap [diaphragm or cervical vault caps] plus spermicidal agent [foam, gel, film, cream, suppository]) or male partner sterilization prior to the female participant's entry into the study, and this male is the sole partner for that participant
Exclusion Criteria:
- Women who have a positive urine pregnancy test
- Women who are breast-feeding
- History of malignancy or neoplastic disease of any organ system (except for localized basal cell skin carcinoma), treated or untreated, within the past 5 years prior to screening, regardless of whether there is evidence of local recurrence or metastases, clinically relevant chronic or acute infectious illnesses or febrile infections within two weeks prior to start of the study, History (within 5 years prior to study start) or any evidence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinological, metabolic, autoimmune, neurological, psychiatric or other diseases at screening, participants who have used medications or therapies that could interfere with study evaluations and have not had the proper washout period from these medications or therapies or are anticipated to require any concomitant intranasal medication during that period or at any time throughout the study, any condition that prohibits the participant from actuating nasal spray devices (severe rheumatoid arthritis; deformed hands and fingers; missing fingers), Nasal disease(s) likely to affect deposition of intranasal medication, such as acute or chronic sinusitis, rhinitis medicamentosa, clinically significant polyposis, or clinically significant nasal structural abnormalities
- Known or suspected intolerance or hypersensitivity to any of the study medications, excipients, investigational device material, or to medications of similar chemical classes, any history of drug hypersensitivity, asthma, urticaria, or other significant allergic diathesis, known or suspected contraindications, including history of allergy, or photosensitivity to study medication/s
- Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of screening or 5 half-lives of the other clinical studies investigational drug, whichever is longer, Previously enrolled in the current study
- Current smoker or smoked or used nicotine containing products within 5 years of screening, history (within 5 years prior to study start) or evidence of illicit drug abuse or if the investigator suspects current drug use with drug classes that include but are not limited to barbiturates, amphetamines, benzodiazepines, cocaine, opiates, cannabis or any other illicit drugs (verified by urine drug screening or other reliable evidence), history or evidence of current alcohol abuse or if participant reports a regular average alcohol consumption exceeding 18 g (women) or 35 g (men) of pure alcohol per day, i.e. 1 drink/day for women or 2 drinks/day for men (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of screening
- Non-acceptance of standardized food and beverages throughout each confined study period, Ingestion of food containing poppy seeds (muffins, bagels, cakes, etc) within 24 hours of admission to the study site
- Persons directly or indirectly involved in the execution of this protocol, including employees of the contract research organization (CRO) and persons related to them, an employee of the sponsor or the study site or members of their immediate family
- On nasal examination, the presence of any superficial or moderate nasal mucosal erosion, nasal mucosal ulceration, or nasal septum perforation (Grade 1B - 4) during the screening visit or Day -1, Participants with difficulty in using the nasal spray applicator, "Vulnerable" individual (as defined by the Institutional Review Board (IRB) e.g. incarcerated person), any condition not identified in the protocol that in the opinion of the investigator would confound the evaluation and interpretation of the study data or may put the participant at risk, no consumption of alcohol-containing products within 24 hours before confinement and throughout confined study period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Carbomer 980
Participants will be administered test product (nasal spray) containing 0.5% carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
|
Test product containing 0.5% carbomer 980 gel
|
PLACEBO_COMPARATOR: Placebo
Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
|
Reference product containing vehicle without 0.5% carbomer 980 gel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidences of nasal mucosal changes of ≥ Grade 1B
Time Frame: Baseline to Day 8
|
The investigators will perform a thorough examination using nasal mucosal grading scale: Grade 0 = No abnormal findings, Grade 1A = focal nasal mucosal irritation (inflammation, erythema or hyperemia), Grade 1B = superficial nasal mucosal erosion, Grade 2 = moderate nasal mucosal erosion
|
Baseline to Day 8
|
Incidence of moderate or severe mucosal bleeding
Time Frame: Baseline to Day 8
|
The investigators will perform a thorough examination using mucosal bleeding scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe
|
Baseline to Day 8
|
Incidence of moderate or severe crusting of mucosa
Time Frame: Baseline to Day 8
|
The investigators will perform a thorough examination using crusting of mucosa scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe
|
Baseline to Day 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Baseline to Day 8
|
All adverse events reported by participants will be recorded.
|
Baseline to Day 8
|
Change from baseline in Blood pressure
Time Frame: Baseline to Day 8
|
Systolic and diastolic BP will be measured three times after the participant has been sitting for 5 minutes using an automated validated device, e.g.
OMRON, with an appropriately sized cuff.
The repeat sitting measurements will be made at 1-2 minute intervals and the mean/average of the three measurements will be recorded.
|
Baseline to Day 8
|
Change from baseline in pulse
Time Frame: Baseline to Day 8
|
Pulse will be measured three times after the participant has been sitting for 5 minutes using an automated validated device, e.g.
OMRON, with an appropriately sized cuff.
The repeat sitting measurements will be made at 1-2 minute intervals and the mean/average of the three measurements will be recorded.
|
Baseline to Day 8
|
Change from baseline in respiration rate
Time Frame: Baseline to Day 8
|
The rate will be measured by counting the number of breaths for one minute (counting how many times the chest rises).
|
Baseline to Day 8
|
Change from baseline in oral body temperature
Time Frame: Baseline to Day 8
|
Oral body temperature will be measured.
Reference range (Oral body temperature between 35.0 º Celsius (C) and 37.5 ºC)
|
Baseline to Day 8
|
Change from baseline in Hematology
Time Frame: Baseline to Day 8
|
Hemoglobin (Hb), hematocrit (Ht), red blood cell (RBC) count (including mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), white blood cell (WBC) count with differential and platelet count will be measured.
|
Baseline to Day 8
|
Change from baseline in clinical Chemistry
Time Frame: Baseline to Day 8
|
Electrolytes (sodium, potassium, chloride, calcium, phosphorous), substrates (Blood Urea Nitrogen [BUN], creatinine, total bilirubin, total protein, albumin, uric acid, and C-reactive protein), and enzymes (aspartate amino transferase [AST], alanine amino transferase [ALT], alkaline phosphatase (ALP), gamma glutamyl transferase [GGT], creatine kinase [CK]) will be measured.
|
Baseline to Day 8
|
Change from baseline in virus Serology
Time Frame: Baseline to Day 8
|
Serology will be performed only for Hepatitis B Surface Antigen (HBs Ag), Hepatitis B core antibody [anti-HBc] (Immunoglobulin G [IgG] + Immunoglobulin M [IgM]), anti-HCV Ab [Hepatitis C Virus antibody], Human Immunodeficiency Virus [HIV] 1 and HIV 2 antibodies.
|
Baseline to Day 8
|
Change from baseline in urinalysis
Time Frame: Baseline to Day 8
|
Specific gravity, nitrite, protein including microalbuminuria, glucose, ketones as well as blood WBC and RBC sediments will be assessed.
(
|
Baseline to Day 8
|
Change from baseline in urine drug & cotinine screen
Time Frame: Baseline to Day 8
|
: Urine will be collected and tested for cotinine and the following drugs or illicit substances: barbiturates, benzodiazepines, amphetamines, cocaine, opiates, and cannabis.
|
Baseline to Day 8
|
Change from baseline in pregnancy and assessments of fertility
Time Frame: Baseline to Day 8
|
A urine dipsick test will be performed.
|
Baseline to Day 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 11, 2016
Primary Completion (ACTUAL)
July 10, 2016
Study Completion (ACTUAL)
July 18, 2016
Study Registration Dates
First Submitted
June 29, 2016
First Submitted That Met QC Criteria
July 11, 2016
First Posted (ESTIMATE)
July 14, 2016
Study Record Updates
Last Update Posted (ACTUAL)
June 29, 2017
Last Update Submitted That Met QC Criteria
June 28, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 205636
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Common Cold
-
Cardiff UniversityCompletedCommon Cold/FluUnited Kingdom
-
Perrigo CompanyGlaxoSmithKline; Pfizer; McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. and other collaboratorsCompletedNasal Congestion Associated With the Common ColdUnited States
-
NovartisCompletedCommon Cold Associated With CoughCanada
-
Probi ABCompletedAcute Upper Respiratory Tract Infections (Common Cold)Italy
-
Ache Laboratorios Farmaceuticos S.A.Suspended
-
Beijing Da-an Bio-technology Co., Ltd.Unknown
-
Brainfarma Industria Química e Farmacêutica S/ATechtrials Pesquisa e Tecnologia Ltda; PharmagenixUnknown
-
NovartisCompletedSore Throat Due to a Common ColdGermany
-
Boehringer IngelheimCompleted
-
Lund UniversityCoradil ABEnrolling by invitation
Clinical Trials on Carbomer 980
-
GlaxoSmithKlineCompleted
-
University of MiamiCompletedPruritusUnited States
-
Cairo UniversityUnknown
-
Association pour le Développement et l'Organisation...Completed
-
Daniela Prócida RaggioAcademic Centre for Dentistry in AmsterdamCompletedDental Caries Extending Into Dentine | Caries Involving Multiple Surfaces of Tooth | Dental Caries on Chewing Surface of ToothBrazil
-
KLE Society's Institute of Dental SciencesCompletedChronic Periodontitis
-
University Hospital Bispebjerg and FrederiksbergUnknownBladder CancerDenmark
-
Xiaodong ZhouCompletedPrimary Open-angle Glaucoma
-
Okan UniversityBezmialem Vakif UniversityCompleted
-
Huaxia Eye Hospital GroupCompletedDry Eye | Tear Film | Lipid Layer | Liposic | Tears Naturale ForteChina